NGNE
Neurogene Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.25
−2.92%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$23.56
From 52W high−45.73%
Volume543886.00
Market cap$465.26M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$23.56
From 52W high
−45.73%
Volume
543886.00
Market cap
$465.26M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
32.9
MomentumView details →
1D Return
−2.92%
YTD Return
+13.30%
SummaryUpdated Jun 1, 2026
Neurogene Inc. (NASDAQ:NGNE) is a clinical-stage biotechnology company founded in 2014 and headquartered in New York, New York. The company specializes in developing gene therapies for rare neurological diseases, focusing on conditions that primarily affect children and have limited or no treatment options. Since its initial public offering in 2014, Neurogene has been advancing its pipeline of investigational treatments through clinical trials, with its lead programs targeting Rett syndrome and Batten disease.
Similar companies
Latest newsMore news →
Neurogene Inc. granted non-qualified stock options to purchase an aggregate of 8,340 shares of its common stock to five new employees on October 5, 2026.11d agoNeurogene Inc. granted non-qualified stock options to purchase 38,330 shares of common stock to two new employees as inducement grants on September 1, 2026.42d agoNeurogene Inc. completed an oversubscribed financing raising approximately $144 million in gross proceeds, with net proceeds of approximately $134.8 million from a July 2026 public offering.67d ago